Table 4.

Frequency of Systemic Therapy by Specific Agent Administration in Stage¹ IIIB/IV non-Small Cell Lung Cancer Patients by Year of Diagnosis, Patterns of Care (n = 1098).

	1996		2005		2010
Systemic Therapy	N2	%3	N2	%3	N2	%3	P4
Bevacizumab	-	-	24	4	99	22	<0.01
Carboplatin	92	50	278	72	351	73	<0.01
Cisplatin	71	35	55	14	103	18	<0.01
Docetaxel	**	2	86	17	78	13	<0.01
Erlotinib	-	-	69	14	124	17	0.43
Etoposide (VP16)	65	32	26	5	43	5	<0.01
Gemcitabine	-	-	85	19	92	21	0.62
Paclitaxel (Taxol)	55	28	181	50	209	42	<0.01
Pemetrexed	-	-	22	6	187	38	<0.01
Vinorelbine	27	18	24	4	22	5	0.01

¹American Joint Committee on Cancer (1996: 3^rd Edition; 2005–2010: 6^th Edition)

²Unweighted number of patients receiving the systemic therapy agent.

³Weighted percentage of patients receiving the systemic therapy agent.

⁴Χ² across years.

^**Cell size less than 5, results masked for confidentiality.

- Agent not assessed.